Research on Prospective Pharmacorrection Medications for First-degree Obesity Treatment among Non-natural Substances Containing Chalcogenamido Groups

Alimentary obesity is an important social problem for all developed countries. A variety of factors affects gain of body weight. among which hypodynamia, which is caused by widespread automation. To date, the human diet increases the palm oil content due to its low cost and long shelf life. Detailed research of the effect of excessive amount of palm oil on the body state is very relevant. In the modern world, it is important to search for highly effective and safe medicines for weight loss treatment of metabolic syndrome consequences. 

This work is dedicated to a search for effective and safe  pharmacorrection medications for the first-degree obesity treatment, as the result of excessive consumption of palm oil during a long period of time. 

Our studies have shown that two new compounds containing chalcogenamide groups have the property of reducing weight. The experiment was performed on 24 white non-linear sexually mature rats of both sexes, which weighed 120-180g. The animals were divided into 4 groups. The animals of the intact group were kept on a standard diet of the vivarium of the State Institution «Lugansk State Medical University», LPR. The second group, the control group, has been receiving palm oil at a dose of 30 g/kg to a daily ration for a period of 6 weeks. The rats of the third and fourth groups have been receiving samples of two new organic compounds 1 and 2).The compounds were administered intragastrically at a dose of 2.5 mg/kg for 2 weeks after a six-week high-fat diet. Once every 7 days the rats were weighed to assess the dynamics of changes in their weight.

The body weight of animals had increased by 121% after a six-week high-fat diet. After the first week of pharmacorrection, the  third group showed a decrease in weight by 12.17%, and after the second week the animals lost another 10.75%. During the two-week period of administration of the substance 1 the weight of the rats decreased by a factor of 1,27 and approached the values of the body weight of animals of the intact group. There were no animal deaths in this group, the behavioral reactions of rats were adequate. In the latter days of research the flabbiness of the hair-coat was noted. In the fourth experimental group, the mass decreased by 8.02% during the first two-week period. The death of animals was absent, behavioral reactions were adequate.

The performed studies have shown that substances  1 {3',9'-dibenzyl-6'-selenoxo-3',4',9',10'- tetrahydro-2'H-spiro[cyclohexane-1,12'-[1,3,5,9] tetraaza[7,11]-methano[1,3,5]triazino[1,2-a] [1,5]diazocine]-7',11'(6'H,8'H)-dicarbonitrile} and 2 {4-(2-chlorophenyl)-2-({[3-methyl-2,6-dioxo-7-(2-oxo- 2-phenylethyl)-2,3,6,7-tetrahydro-1H-purin-8-yl]methyl} thio)-5,6,7,8-tetrahydroquinoline-3-carbonitrile} possessed the properties of prospective pharmacorrection medications for alimentary obesity treatment.